"The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment according to a new study. The researchers found that among patients whose cancer had spread those who took the drug lived a median of . months longer than those who received a physicianchosen treatment  . months versus . months. The study included  women who were given eribulin and  women who received treatment of the physicians choice which was defined as any singleagent chemotherapy hormonal or biological treatment approved for cancer treatment radiotherapy or symptomatic treatment alone. The most common side effects in both groups were fatigue and depletion of white blood cells. Numbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study  or  percent. The study known as the EMBRACE trial was funded by Eisai Inc. which markets eribulin. Dr. Javier Cortes of the Vall dHebron University Hospital and Vall dHebron Institute of Oncology in Barcelona Spain and colleagues published the findings in the March  online edition of The Lancet. This global phase  study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer for whom there was previously no chemotherapy treatment with proven survival benefit the authors wrote. In a related editorial Drs. Nancy U. Lin and Harold J. Burstein of the DanaFarber Cancer Institute and Harvard Medical School in Boston said EMBRACE provides much needed highlevel evidence for chemotherapy use in patients with heavily pretreated breast cancer. And that evidence suggests that the methods to treat advanced breast cancer are growing the treatment challenge in refractory disease is a little bit less daunting and the treatment results are a little bit better than they were before. Commenting on the study Dr. Stephanie Bernik chief of surgical oncology at Lenox Hill Hospital in New York City said The findings of this trial are exciting because they will propel eribulin into wider use. This drug shows much promise and it should certainly be included in additional trials to fully establish its benefit.  It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin she added. More information The Metastatic Breast Cancer Network has more about metastatic breast cancer httpmbcnetwork.orgeducation. SOURCE Stephanie Bernik M.D. F.A.C.S. chief of surgical oncology at Lenox Hill Hospital New York City N.Y. The Lancet news release March"